Kalaris Therapeutics Inc
KLRS10.060USD
+0.930+10.19%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
188.15MMarket Cap
LossP/E TTM
More Details of Kalaris Therapeutics Inc Company
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Kalaris Therapeutics Inc Info
Ticker SymbolKLRS
Company nameKalaris Therapeutics Inc
IPO dateJul 30, 2020
CEOOxtoby (Andrew)
Number of employees6
Security typeOrdinary Share
Fiscal year-endJul 30
Address400 Connell Drive
CityBERKELEY HEIGHTS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07922
Phone16502492727
Websitehttps://kalaristx.com/
Ticker SymbolKLRS
IPO dateJul 30, 2020
CEOOxtoby (Andrew)
Company Executives of Kalaris Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Director
Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Executive Chairman of the Board
Executive Chairman of the Board
130.55K
+1.18%
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
--
Mr. Andrew Oxtoby
Mr. Andrew Oxtoby
Chief Executive Officer, Principal Executive Officer, Director
Chief Executive Officer, Principal Executive Officer, Director
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Director
Director
--
--
Dr. Anthony P. Adamis, M.D.
Dr. Anthony P. Adamis, M.D.
Director
Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Director
Director
--
--
Mr. Brett R. Hagen
Mr. Brett R. Hagen
Chief Accounting Officer
Chief Accounting Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Director
Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Executive Chairman of the Board
Executive Chairman of the Board
130.55K
+1.18%
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
--
Mr. Andrew Oxtoby
Mr. Andrew Oxtoby
Chief Executive Officer, Principal Executive Officer, Director
Chief Executive Officer, Principal Executive Officer, Director
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Samsara BioCapital, LLC
61.21%
ElevateBio LLC
3.88%
Ferrara (Napoleone)
2.69%
F2 MG Ltd
2.28%
Tang Capital Management, LLC
2.24%
Other
27.70%
Shareholders
Shareholders
Proportion
Samsara BioCapital, LLC
61.21%
ElevateBio LLC
3.88%
Ferrara (Napoleone)
2.69%
F2 MG Ltd
2.28%
Tang Capital Management, LLC
2.24%
Other
27.70%
Shareholder Types
Shareholders
Proportion
Venture Capital
61.21%
Individual Investor
6.43%
Corporation
6.16%
Hedge Fund
4.35%
Investment Advisor
3.83%
Investment Advisor/Hedge Fund
1.42%
Other
16.59%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
193
13.23M
70.72%
-1.05M
2025Q2
227
16.58M
88.66%
+10.64M
2025Q1
234
16.39M
87.75%
+10.95M
2024Q4
237
3.88M
53.28%
-1.58M
2024Q3
243
4.43M
85.21%
-1.20M
2024Q2
253
4.51M
86.91%
-1.04M
2024Q1
252
4.61M
89.02%
-783.99K
2023Q4
254
4.25M
88.46%
-716.47K
2023Q3
253
4.79M
104.12%
+25.72K
2023Q2
259
4.80M
104.70%
+638.53K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Samsara BioCapital, LLC
11.45M
61.21%
--
--
Jun 30, 2025
ElevateBio LLC
724.99K
3.88%
--
--
Jun 25, 2025
Ferrara (Napoleone)
504.00K
2.69%
--
--
Jun 25, 2025
F2 MG Ltd
427.31K
2.28%
-1.00
-0.00%
Jun 25, 2025
Tang Capital Management, LLC
360.86K
1.93%
+51.64K
+16.70%
Jun 30, 2025
Invus Public Equities Advisors, LLC
282.59K
1.51%
--
--
Jun 30, 2025
Patel (Samirbhai Chandrakant)
252.00K
1.35%
+252.00K
--
Mar 18, 2025
Rezai (Kourous)
203.67K
1.09%
+203.67K
--
Jun 25, 2025
The Vanguard Group, Inc.
129.84K
0.69%
+14.75K
+12.82%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Equity ETF
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 10, 2025
Merger
23→1
Date
Type
Ratio
Jan 10, 2025
Merger
23→1
FAQs
Who are the top five shareholders of Kalaris Therapeutics Inc?
The top five shareholders of Kalaris Therapeutics Inc are:
Samsara BioCapital, LLC holds 11.45M shares, accounting for 61.21% of the total shares.
ElevateBio LLC holds 724.99K shares, accounting for 3.88% of the total shares.
Ferrara (Napoleone) holds 504.00K shares, accounting for 2.69% of the total shares.
F2 MG Ltd holds 427.31K shares, accounting for 2.28% of the total shares.
Tang Capital Management, LLC holds 360.86K shares, accounting for 1.93% of the total shares.
Samsara BioCapital, LLC holds 11.45M shares, accounting for 61.21% of the total shares.
ElevateBio LLC holds 724.99K shares, accounting for 3.88% of the total shares.
Ferrara (Napoleone) holds 504.00K shares, accounting for 2.69% of the total shares.
F2 MG Ltd holds 427.31K shares, accounting for 2.28% of the total shares.
Tang Capital Management, LLC holds 360.86K shares, accounting for 1.93% of the total shares.
What are the top three shareholder types of Kalaris Therapeutics Inc?
The top three shareholder types of Kalaris Therapeutics Inc are:
Samsara BioCapital, LLC
ElevateBio LLC
Ferrara (Napoleone)
Samsara BioCapital, LLC
ElevateBio LLC
Ferrara (Napoleone)
How many institutions hold shares of Kalaris Therapeutics Inc (KLRS)?
As of 2025Q3, 193 institutions hold shares of Kalaris Therapeutics Inc, with a combined market value of approximately 13.23M, accounting for 70.72% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -17.94%.
What is the biggest source of revenue for Kalaris Therapeutics Inc?
In FY2021, the -- business generated the highest revenue for Kalaris Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
